// App-Quantinova.ai

1295 : Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens

Researchers

Presenter

  • Andrea GS Pepper

Principal Investigators

  • Antonella Zucchetto

  • Kevin Norris

  • Erika Tissino

  • Jerry Polesel

  • Zarni Soe

  • David Allsup

  • Anna Hockaday

  • Pei Loo Ow

  • Peter Hillmen

  • Andrew Rawstron

  • Daniel Catovsky

  • Riccardo Bomben

  • Duncan M Baird

  • Christopher Fegan

  • Valter Gattei

  • Chris Pepper

Medical Centers

  • University of Sussex, Brighton and Sussex Medical School, Falmer, GBR

  • Clinical and Experimental Onco-Hematology, Centro di Riferimento Oncologico, Aviano, Italy

  • Institute of Cancer & Genetics, Cardiff University, Cardiff, Wales, United Kingdom

  • Clinical and Experimental Onco-Hematology, Centro di Riferimento Oncologico, Aviano, Italy

  • Unit of Cancer Epidemiolog, IRCCS Centro Di Riferimento Oncologico, Aviano, Italy

  • SLM Haematology, Leeds Teaching Hospitals NHSTrust, Leeds, United Kingdom

  • Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Owston Ferry, ENG, United Kingdom

  • Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom

  • University of Leeds, Leeds, UK

  • Department of Diabetes and Endocrinology, St James University Hospital, Leeds, United Kingdom

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Division of Cancer and Genetics, Cardiff University, Cardiff, United Kingdom

  • Division of Cancer and Genetics, Cardiff University, Cardiff, United Kingdom

  • Clinical and Experimental Onco-Hematology, Centro di Riferimento Oncologico, Aviano, Italy

  • Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom

Locations

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Tumor protein p53

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

  • TP53

Outcome

  • N/A

Study Design

  • Randomized

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved